A Phase 3 interventional study of Vedolizumab Placebo and Vedolizumab in Hematopoietic Stem Cells, sponsored by Millennium Pharmaceuticals, Inc.. Completed at 139 sites in 27 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2023-06-06.
Sponsored by Millennium Pharmaceuticals, Inc. (part of Takeda) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to evaluate the efficacy of vedolizumab when added to background aGvHD prophylaxis regimen compared to placebo and background aGvHD prophylaxis regimen on intestinal aGvHD-free survival by Day +180 in participants who receive allo-HSCT as treatment for a hematologic malignancy or myeloproliferative disorder.
The drug being tested in this study is called vedolizumab. Vedolizumab is being tested to treat people who are undergoing allo-HSCT transplantation. This study will look at the efficacy and safety of vedolizumab in the prophylaxis of intestinal aGvHD in participants undergoing allo-HSCT transplantation.
The study will enroll approximately 558 participants. Participants will be randomly assigned (by chance, like flipping a coin) in 1:1 ratio to one of the two treatment groups-which will remain undisclosed to the participant and study doctor during the study (unless there is an urgent medical need) along with background GvHD prophylaxis regimen:
This multi-center trial will be conducted Worldwide. The overall time to participate in this study is 12 months.
Millennium Pharmaceuticals, Inc. is the lead sponsor of 178 studies on the registry; none are open to participants now.
Of its 74 completed or terminated interventional studies of FDA-regulated products, 73 (99%) have results posted.
First submitted after Millennium Pharmaceuticals, Inc. became part of Takeda.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Vedolizumab placebo-matching, intravenous (IV) infusion, once on Day -1 along with background graft-versus-host disease (GvHD) prophylaxis regimen prior to Allo-HSCT and once on Days +13, +41, +69, +97, +125, and +153 post Allo-HSCT up to the end of study treatment (up to 182 days).
Drug: Vedolizumab Placebo
Vedolizumab 300 mg, IV infusion, once on Day -1 along with background GvHD prophylaxis regimen prior to Allo-HSCT and once on Days +13, +41, +69, +97, +125, and +153 post Allo-HSCT up to the end of study treatment (up to 182 days).
Drug: Vedolizumab
Vedolizumab placebo-matching IV infusion.
Vedolizumab IV infusion.
Also known as: MLN0002
Intestinal aGvHD-Free Survival After Allo-HSCT by +180 Days
Intestinal aGvHD Free Survival is the time from the date of first study drug administration (Day-1) to intestinal aGvHD event/death, where an event is defined as death due to any cause or Stage 1-4 intestinal involvement per Acute Graft versus-Host Disease Clinical Stage criteria. Data was censored for participants who have not had the intestinal aGvHD event or died or have had the event after pre-specified timing, e.g., last contact or Day +180 after allo HSCT whichever occurs first.
Time frame: From the date of first dose of study drug to first documented intestinal aGvHD or death, whichever occurs first up to +180 days
Intestinal aGvHD-Free and Relapse-Free Survival
Intestinal aGvHD and Relapse Free Survival is the time from the date of first study drug administration (Day-1) to intestinal aGvHD event/death/relapse, where an event is defined as death or Stage 1-4 intestinal involvement per Acute Graft versus-Host Disease Clinical Stage criteria, or relapse. It will be censored for participants who have not had the event or have had the event after pre-specified timing, e.g., last contact or Day +180 after allo-HSCT whichever occurs first.
Time frame: From the date of first dose of study drug to first documented intestinal aGvHD, death or relapse, whichever occurs first up to Day +180
Grade C-D aGvHD-Free Survival
Grade C-D aGvHD Free Survival is the time from the date of first study drug administration (Day-1) to GvHD event/death, where an event is defined as Grade C-D aGvHD any organ involvement per International Bone Marrow Transplant Registry Database (IBMTR) Severity Index for aGvHD or death. It will be censored for participants who have not had the event or have had the event after pre-specified timing, eg, last contact or Day +180 after allo-HSCT whichever occurs first.
Time frame: From the date of first dose of study drug to first documented Grade C-D aGvHD or death, whichever occurs first up to Day +180
Nonrelapse Mortality (NRM)
Non-relapse mortality is the time from the date of first study drug administration (Day-1) to death without occurrence of a relapse. Data was censored for participants who have not had the event or have had the event after pre-specified timing, e.g., last contact or Day +180 after allo HSCT whichever occurs first.
Time frame: From the date of first dose of study drug to first documented death without relapse, up to Day +180
Overall Survival (OS)
Overall Survival by Days +180 is the time from the date of first study drug administration (Day-1) to death from any cause.
Time frame: From the date of first dose of study drug to first documented death up to Day +180
Grade B-D aGvHD-Free Survival
Grade B-D aGvHD Free Survival is the time from the date of first study drug administration (Day-1) to aGvHD event or death, where an event is defined as death or grade B-D any organ involvement per IBMTR Severity Index for aGvHD.
Time frame: From the date of first dose of study drug to first documented grade B-D aGvHD or death, whichever occurs first up to Day +180
Participants took part in the study at 95 investigative sites in Canada, United States, Argentina, Brazil, Belgium, France, Germany, Italy, Norway, Portugal, Spain, Sweden, Switzerland, United Kingdom, Austria, Greece, Hungary, Poland, Israel, Romania, Russia, Australia, Japan, Republic of Korea and Singapore from 6 February 2019 to 9 May 2022.
| Milestone | Placebo | Vedolizumab 300 mg |
|---|---|---|
| Started | 169 | 174 |
| Safety analysis set | 165 | 169 |
| Full analysis set | 165 | 168 |
| Completed | 98 | 117 |
| Not completed | 71 | 57 |
| Withdrew: Adverse event | 5 | 6 |
| Withdrew: Protocol deviation | 3 | 0 |
| Withdrew: Withdrawal by subject | 18 | 16 |
| Withdrew: Site termination | 1 | 0 |
| Withdrew: Unsatisfactory therapeutic response | 5 | 3 |
| Withdrew: Death | 33 | 26 |
| Withdrew: Death (covid-19-related) | 1 | 0 |
| Withdrew: Reason not specified | 5 | 5 |
| Withdrew: Other (covid-19-related) | 0 | 1 |
Intestinal aGvHD Free Survival is the time from the date of first study drug administration (Day-1) to intestinal aGvHD event/death, where an event is defined as death due to any cause or Stage 1-4 intestinal involvement per Acute Graft versus-Host Disease Clinical Stage criteria. Data was censored for participants who have not had the intestinal aGvHD event or died or have had the event after pre-specified timing, e.g., last contact or Day +180 after allo HSCT whichever occurs first.
| days | Placebo | Vedolizumab 300 mg |
|---|---|---|
| Intestinal aGvHD-Free Survival After Allo-HSCT by +180 Days | NA (14 to 182) | NA (2 to 182) |
Intestinal aGvHD and Relapse Free Survival is the time from the date of first study drug administration (Day-1) to intestinal aGvHD event/death/relapse, where an event is defined as death or Stage 1-4 intestinal involvement per Acute Graft versus-Host Disease Clinical Stage criteria, or relapse. It will be censored for participants who have not had the event or have had the event after pre-specified timing, e.g., last contact or Day +180 after allo-HSCT whichever occurs first.
| days | Placebo | Vedolizumab 300 mg |
|---|---|---|
| Intestinal aGvHD-Free and Relapse-Free Survival | NA (14 to 182) | NA (2 to 182) |
Grade C-D aGvHD Free Survival is the time from the date of first study drug administration (Day-1) to GvHD event/death, where an event is defined as Grade C-D aGvHD any organ involvement per International Bone Marrow Transplant Registry Database (IBMTR) Severity Index for aGvHD or death. It will be censored for participants who have not had the event or have had the event after pre-specified timing, eg, last contact or Day +180 after allo-HSCT whichever occurs first.
| days | Placebo | Vedolizumab 300 mg |
|---|---|---|
| Grade C-D aGvHD-Free Survival | NA (12 to 182) | NA (12 to 182) |
Non-relapse mortality is the time from the date of first study drug administration (Day-1) to death without occurrence of a relapse. Data was censored for participants who have not had the event or have had the event after pre-specified timing, e.g., last contact or Day +180 after allo HSCT whichever occurs first.
| days | Placebo | Vedolizumab 300 mg |
|---|---|---|
| Nonrelapse Mortality (NRM) | NA (14 to 182) | NA (19 to 182) |
Overall Survival by Days +180 is the time from the date of first study drug administration (Day-1) to death from any cause.
| days | Placebo | Vedolizumab 300 mg |
|---|---|---|
| Overall Survival (OS) | NA (14 to 182) | NA (19 to 182) |
Grade B-D aGvHD Free Survival is the time from the date of first study drug administration (Day-1) to aGvHD event or death, where an event is defined as death or grade B-D any organ involvement per IBMTR Severity Index for aGvHD.
| days | Placebo | Vedolizumab 300 mg |
|---|---|---|
| Grade B-D aGvHD-Free Survival | NA (12 to 182) | NA (12 to 182) |
Collected over From the first dose of study drug up to end of study (up to 39 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 34/169 (20.1%) | 114/165 (69.1%) | 164/165 (99.4%) |
| Vedolizumab 300 mg | 26/174 (14.9%) | 120/169 (71%) | 169/169 (100%) |
| Event | Placebo | Vedolizumab 300 mg |
|---|---|---|
| Acute graft versus host disease in intestineImmune system disorders | 16/165 | 6/169 |
| PyrexiaGeneral disorders | 13/165 | 13/169 |
| SepsisInfections and infestations | 9/165 | 4/169 |
| Acute myeloid leukaemia recurrentNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 9/165 | 9/169 |
| Alanine aminotransferase increasedInvestigations | 4/165 | 9/169 |
| Febrile neutropeniaBlood and lymphatic system disorders | 8/165 | 7/169 |
| PneumoniaInfections and infestations | 8/165 | 5/169 |
| Acute kidney injuryRenal and urinary disorders | 8/165 | 3/169 |
| DiarrhoeaGastrointestinal disorders | 4/165 | 6/169 |
| Cytomegalovirus infection reactivationInfections and infestations | 2/165 | 6/169 |
| Event | Placebo | Vedolizumab 300 mg |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 102/165 | 95/169 |
| StomatitisGastrointestinal disorders | 90/165 | 90/169 |
| NauseaGastrointestinal disorders | 83/165 | 85/169 |
| PyrexiaGeneral disorders | 62/165 | 80/169 |
| AnaemiaBlood and lymphatic system disorders | 72/165 | 68/169 |
| Acute Graft Versus Host Disease in SkinImmune system disorders | 65/165 | 67/169 |
| Febrile NeutropeniaBlood and lymphatic system disorders | 54/165 | 67/169 |
| HypomagnesaemiaMetabolism and nutrition disorders | 52/165 | 60/169 |
| HeadacheNervous system disorders | 58/165 | 58/169 |
| VomitingGastrointestinal disorders | 55/165 | 41/169 |
Full Analysis Set (FAS) included all participants who were randomized, received at least 1 dose of the treatment, and under-went allo-HSCT.
| Age, Continuous(years) | Placebo | Vedolizumab 300 mg | Total |
|---|---|---|---|
| Mean | 51.9 ± 14.49 | 50.8 ± 14.41 | 51.4 ± 14.44 |
| Sex: Female, Male(Participants) | Placebo | Vedolizumab 300 mg | Total |
|---|---|---|---|
| Female | 106 | 103 | 209 |
| Male | 59 | 65 | 124 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Vedolizumab 300 mg | Total |
|---|---|---|---|
| Hispanic or Latino | 9 | 16 | 25 |
| Not Hispanic or Latino | 133 | 133 | 266 |
| Unknown or Not Reported | 23 | 19 | 42 |
| Race (NIH/OMB)(Participants) | Placebo | Vedolizumab 300 mg | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 36 | 29 | 65 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 2 | 3 | 5 |
| White | 114 | 121 | 235 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 13 | 15 | 28 |
Showing the first 100 of 139 sites across 27 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Feb 2019 to primary completion in Feb 2022, 36 months.
Results were first posted in Apr 2023, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vedolizumab
Millennium Pharmaceuticals, Inc. →